Cencora, Inc. Expected to Earn Q3 2024 Earnings of $3.14 Per Share (NYSE:COR)

Cencora, Inc. (NYSE:CORFree Report) – Zacks Research lowered their Q3 2024 EPS estimates for Cencora in a report issued on Wednesday, May 22nd. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings of $3.14 per share for the quarter, down from their previous forecast of $3.20. The consensus estimate for Cencora’s current full-year earnings is $13.44 per share. Zacks Research also issued estimates for Cencora’s Q4 2024 earnings at $3.19 EPS and Q4 2025 earnings at $3.91 EPS.

Cencora (NYSE:CORGet Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. The business had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.50 EPS.

Other research analysts also recently issued reports about the stock. Citigroup boosted their price objective on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. StockNews.com downgraded shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. Robert W. Baird upped their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Mizuho upped their target price on shares of Cencora from $192.00 to $224.00 and gave the stock a “neutral” rating in a research report on Monday, February 5th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a research report on Monday, February 26th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $233.90.

Check Out Our Latest Stock Analysis on Cencora

Cencora Stock Down 0.4 %

Shares of Cencora stock opened at $218.89 on Friday. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. The company’s fifty day simple moving average is $233.86 and its two-hundred day simple moving average is $222.31. The company has a market cap of $43.66 billion, a P/E ratio of 23.95, a PEG ratio of 1.53 and a beta of 0.47. Cencora has a 12-month low of $163.37 and a 12-month high of $246.75.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a yield of 0.93%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio is currently 22.32%.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 6,977 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the transaction, the executive vice president now owns 8,246 shares in the company, valued at approximately $1,963,537.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Cencora news, EVP Elizabeth S. Campbell sold 6,977 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $238.12, for a total transaction of $1,661,363.24. Following the transaction, the executive vice president now owns 8,246 shares in the company, valued at approximately $1,963,537.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $235.09, for a total transaction of $13,532,720.76. Following the transaction, the chief operating officer now owns 24,412 shares in the company, valued at approximately $5,739,017.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,934,685 shares of company stock worth $417,739,921. Company insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Several institutional investors have recently made changes to their positions in COR. Rise Advisors LLC bought a new position in shares of Cencora in the 1st quarter worth approximately $25,000. Legacy Bridge LLC bought a new position in shares of Cencora in the 1st quarter worth approximately $27,000. TCTC Holdings LLC bought a new position in shares of Cencora in the 1st quarter worth approximately $29,000. TFO Wealth Partners LLC bought a new position in shares of Cencora in the 1st quarter worth approximately $30,000. Finally, LRI Investments LLC bought a new position in shares of Cencora in the 1st quarter worth approximately $31,000. Institutional investors own 97.52% of the company’s stock.

About Cencora

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

See Also

Earnings History and Estimates for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.